In multiple myeloma, there are many factors influencing the growth of the malignant clone in direct and indirect manners. BAFF is a growth factor for myeloma cells. The aim of the study was to measure its circulating levels in 54 pretreatment patients, along with serum levels of other proliferation markers, such as interleukins-6, -10, and -15, CRP, and beta-2 microglobulin, as well as bone marrow plasma cell infiltration and expression of Ki-67 PI, in various stages of the disease and after effective treatment in 28 of them. Serum levels of the previously mentioned factors were measured by ELISA, whereas bone marrow plasma cell infiltration and Ki-67 expression were estimated immunohistochemically. All measured parameters were higher in pretreated myeloma patients compared to healthy population and were also increasing with the progression of the disease. They all also decreased after effective therapy. Furthermore, all pretreatment values correlated to each other. BAFF seems to be an important growth factor for myeloma plasma cells. Measuring its serum levels, along with the previously mentioned cytokines, may provide important information regarding the degree of myeloma cells' proliferation. Therefore, they all could be used as markers of proliferation and disease activity. © 2013 Michael G. Alexandrakis et al.
CITATION STYLE
Alexandrakis, M. G., Roussou, P., Pappa, C. A., Messaritakis, I., Xekalou, A., Goulidaki, N., … Tsirakis, G. (2013). Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma. BioMed Research International, 2013. https://doi.org/10.1155/2013/389579
Mendeley helps you to discover research relevant for your work.